1 estimate that providing patients aged 50 years and older at average risk for colorectal cancer with screening colonoscopy every 10 years will reduce colorectal cancer mortality by 64%. These results are similar to those reported by Sonnenberg et al. 2 The standard evidence given in support of this dramatic mortality benefit, which is substantially greater than has been demonstrated for any screening test, is the National Polyp Study.
To the Editor: Dr Frazier and colleagues 1 present a timely costeffectiveness analysis of methods for screening the general population to decrease morality from colorectal cancer. Although colonoscopy, the most sensitive test, is currently the most expensive, costs could decrease dramatically if the procedure were performed by trained, nonphysician technicians under the supervision of a gastroenterologist. The gastroenterologist could supervise a number of technicians simultaneously while personally visualizing suspicious lesions and performing biopsies when appropriate.
Frazier et al quote data from the 1997 Behavioral Risk Factor Surveillance System 2 in which only 20% of respondents reported having had fecal occult blood testing (FOBT) during the preceding year, and only 30% reported having had a proctoscopy or sigmoidoscopy in the preceding 5 years. While patient recall of proctoscopy or sigmoidoscopy is likely to be fairly accurate given the invasiveness of these procedures, recall of FOBT may be poor, as has been shown regarding accuracy of patients' recall of Papanicolaou tests and cholesterol screening. 3 While recall of FOBT may underestimate the true rate of screening, it is likely that FOBT still remains underutilized, as are many other preventive screening measures. 4 Health care organizations and the media need to play a greater role in publicizing the usefulness of screening for early detection of colorectal carcinoma, which can prompt curative treatment of this major killer.
ing the accuracy of DCBE. Second, it appears that Frazier et al performed a 1-way sensitivity analysis, which only permits manipulation of 1 variable at a time. If multiple parameters are incorrect, then adjustment for a single variable can still be misleading. Other studies have found DCBE sensitivity to be 40% to 70% for low-risk polyps, 50% to 80% for high-risk polyps, and 80% to 90% for cancer. 2, 3 Based on my review of the dominant figures within these ranges, I think that the most accurate estimate of DCBE sensitivity for low-risk polyps is 60%; for high-risk polyps, 75%; and for cancer, 85%. In contrast, the base-case figures used in the study were 30%, 50%, and 70%, respectively. Furthermore, the authors used an overall specificity of 86% (range, 80%-98%), which is lower than the more realistic values of 90% for low-risk polyps and 98% for highrisk polyps and cancer. 2, 3 Frazier et al assigned a cost of $296 for DCBE (range, $50-$300), which is at the upper end of their threshold. Medicare currently reimburses $150 for this procedure. It is not surprising that DCBE was dominated in this study. It would be of interest to see how DCBE would fare if Frazier et al inserted all the above values for performance and cost into their base-case example.
Several cost-effectiveness analyses on colorectal cancer screening have yielded differing outcomes. 2, 4 To avoid confusion, it would be beneficial when such discrepancies exist for authors to explain the basis of such variance and what factors in their design represent an improvement over existing analyses that justify accepting conflicting results.
In Reply: Drs Budenholzer and Welch assert that discussions about the cost-effectiveness of colorectal cancer screening may be premature in light of the insufficient evidence about the effectiveness of colonoscopy. We agree that the ideal evidence would be from randomized clinical trials. However, a screening trial of the general population would require a fairly large sample size and long time horizon. Even with a large anticipated risk reduction, the baseline incidence of colorectal cancer is relatively small.
In the interim, we believe that the use of economic models can provide a valuable framework for understanding the tradeoffs between the costs and benefits of screening, particularly in the face of imperfect data. A number of strategies for colorectal cancer screening have been endorsed and are currently being practiced despite imperfect evidence, and we hope that the availability of cost-effectiveness studies will facilitate a more informed discussion of resource allocation. More importantly, current discussions about the cost-effectiveness of screening in no way preclude the continuing search for better effectiveness data. Comprehensive cost-effectiveness analyses that include all proposed strategies for screening can help narrow the choices about which strategies warrant definitive evaluation in a clinical trial.
We agree with Dr Donohoe that the cost of colonoscopy could be reduced if nonphysician technicians performed the test. This would result in more favorable cost-effectiveness ratios for colonoscopy. However, reducing costs would not affect the health gains associated with colonoscopy. In our model, the combined strategy of the FOBT plus sigmoidoscopy every 5 years would remain the most effective strategy. We concur with Donohoe that it behooves health care organizations and the media to more strongly promote and make available preventive health care services that have such potential to save lives.
As in any modeling effort there are uncertainty and variability in the parameter estimates. Dr Glick questions our assumptions regarding the sensitivity, specificity, and cost of DCBE. Our estimates of sensitivity and specificity were based on a double-blinded assessment of the diagnostic performance of colonoscopy vs DCBE conducted as part of the National Polyp Study. 1 We chose that study because we felt that its design best avoided the problems of work-up bias, which tend to overestimate the sensitivity of a test. While our estimate of the cost of DCBE may not reflect the current Medicare reimbursement, our cost estimates for all screening tests were obtained from a single source and thereby should reflect the relative costs of these tests. However, we recognize that variability in the performance and cost of DCBE may exist from center to center. Using the estimates proposed by Glick, we found that offering patients DCBE every 10 years remained dominated in our model and offering DCBE every 5 years had an incremental costeffectiveness ratio of $19000 per life-year gained compared with sigmoidoscopy every 10 years. Offering DCBE every 5 years remained less effective than the combination of FOBT plus sigmoidoscopy every 10 years, which had an incremental costeffectiveness ratio of $27000 per life-year gained compared with DCBE every 5 years.
Drug Dependence as a Chronic Medical Illness
To the Editor: Dr McLellan and colleagues 1 state that drug addiction should be treated as a chronic medical disease. This contradicts our experiences as a sheriff (L.A.) and an emergency department physician (D.L.S.) who regularly encounter patients who provide false histories concerning trauma or pain syndromes, insist on narcotic analgesics, and vigorously refuse nonnarcotic analgesics or follow-up with an office-based physician. Our experience has been that the overwhelming majority of such patients will not agree to enter a drug rehabilitation program or to go to Alcoholics Anonymous or Narcotics Anonymous.
Anecdotally, most patients who have been in rehabilitation experience a relapse or a loss of control of their drug dependency. Only a tiny minority of these patients will follow up with a single physician or medical office for ongoing medical management of their chronic illness. The vast majority of drugdependent individuals do not view their condition as an illness, but rather spend tremendous resources and take great risks, including that of jail or even death, to continue their lifestyle. In our area we have discovered organized groups that travel from physician to physician for the express purpose of obtaining drugs.
Most people who use illegal drugs make a conscious decision to do so. Although we believe that treatment should be available, it must also be accompanied by consequences, such as jail or involuntary commitment, for noncompliance with detoxification. From our observations, many individuals use drugs to insulate themselves from life and its problems. It is impossible to view all drug users and addicts together, but practical experience provides insight into a world that they choose to inhabit. In Reply: Mr Amerson and Dr Smith have failed to understand 3 key points in our article: (1) that substance-dependent individuals are responsible for the onset of their illness; (2) that they are also responsible for active participation in their recovery; and (3) that they should be treated because of the demonstrated public health and safety benefits of treatment, not merely because of compassion for those affected.
Larry Amerson
Responsibility for Onset of Illness. Addiction is initiated by a voluntary act-but it is also true that this initial voluntary behavior is shaped by preexisting genetic factors. These are also brain changes that begin with the very first drug or alcohol uses, which may evolve into compulsive drug taking that is less subject to voluntary control. We are not yet able to explain the brain and cellular changes that transform the initial, voluntary drug-taking behavior into a compulsion.
Responsibility for Recovery. Drug dependence erodes but does not erase a dependent individual's responsibility for control of their behavior. All patients, regardless of their illness, are responsible for actively participating in their recovery. Many patients with chronic illnesses fail to see the importance of their symptoms and thus may ignore physician advice, fail to comply with medication, and engage in behaviors that exacerbate their illnesses. While such patients may not be as disruptive, demanding, or manipulative as alcohol-or drug-dependent patients, the patterns of denial of symptoms, failure to comply with medical care, and subsequent relapse are not peculiar to addiction. One thing that does separate addiction from other illnesses is the waiting lists for treatment throughout the United States, which contradict assertions that addicted persons do not want treatment.
Efficacy as Basis for Treatment. Compassion or sympathy is not the basis for our argument that physicians should treat addicted individuals. Medically oriented treatments are much more effective than socially oriented responses such as incarceration. Also, addiction treatments have been combined effectively with legal sanctions (eg, drug courts and court-mandated treatments) and with civil sanctions (eg, welfare-to-work programs and involvement of child protection services).
Research has provided physicians with even more effective medications and brief interventions to address addiction problems. These new interventions should be taught in medical schools and primary care residencies. Our review suggests that if physicians develop and apply the skills available to diagnose, treat, monitor, and refer patients in the early stages of substance dependence, there will be fewer late-stage emergency department cases such as those that have frustrated and disillusioned Amerson and Smith. hyperexcitability, tachycardia, ataxia, and nystagmus, as well as a phencyclidine-like psychosis" can occur only in dextromethorphan toxicity. Furthermore, they suggest that these findings in patients admitting ecstasy use, but in whom the results of toxicology screens are negative for MDMA and amphetamines, should lead clinicians to consider dextromethorphan toxicity. Both of these statements are misleading.
Each of the above symptoms may arise from MDMA use. Effects of MDMA include tachycardia, hypertension, hyperthermia, hepatitis, myocardial ischemia, elevated antidiuretic hormone levels, serotonin syndrome, cerebral hemorrhage, and psychosis. 2 In those who use pure MDMA, lethargy may represent a postictal state caused by hyponatremia, hyperthermia, or cerebral hemorrhage. Tachycardia, hyperexcitability, tremor, ataxia, nystagmus, and seizures arise from the hyperadrenergic state produced by the drug. Cerebral hemorrhage may also produce seizures as well as focal neurologic findings, and psychosis may arise from chronic amphetamine use. Contrary to the authors' views, these symptoms may arise not from an adulterant, but from the intended drug.
Urine toxicology screens vary in their ability to detect MDMA. 3, 4 A recent survey assessed the proficiency with which clinical laboratories detected MDMA in standardized samples. 5 Approximately one third of the 2734 laboratories evaluated did not detect MDMA, irrespective of method used. The results of urine immunoassay toxic screens, therefore, may be negative in individuals taking MDMA. Consequently, such results may lead to an incorrect diagnosis of dextromethorphan toxicity in patients who actually have MDMA poisoning. The management of toxicity for MDMA is different than that for dextromethorphan. Clinicians should continue to suspect MDMA toxicity even in the presence of a negative urine screen result.
Health Insurance Status of Recent US Immigrants
To the Editor: Dr Ayanian and colleagues 1 state that a significant number of uninsured adults in the United States forgo needed medical attention. However, many of these uninsured persons are not US citizens. A recent Kaiser Family Foundation report states that immigrants make up about 10% of the population, yet account for 20% to 25% of the uninsured population.
2 A significant fraction of these immigrants are in the United States illegally. Legal immigrants are ineligible for Medicare for 5 years. Each legal immigrant must have a sponsor who pledges to provide support for 5 years so that the immigrant does not become a public charge. Even then, Medicaid still provides support for emergency situations.
The insurance problems will only increase as more people immigrate legally and illegally to the United States. A significant part of the problem of adults not being insured in this country can be traced directly to US immigration policy. Illegal immigration must be controlled. Sponsors should be held to their pledges and provide for the health needs of the legal immigrants they sponsor. Immigration should not be a In Reply: Dr LaPorta implies that recent US immigrants account for a substantial proportion of the uninsured population, but this assumption is incorrect. In an analysis of the Census Bureau's Current Population Survey (CPS) by the Kaiser Commission on Medicaid and the Uninsured, only 6% of the 42.1 million uninsured US residents (approximately 2.4 million people) in 1999 were noncitizens who had lived in the US for less than 5 years (Catherine Hoffman, personal communication, December 5, 2000) . In contrast, 34.7 million uninsured people (82%) were US citizens, and 5.0 million uninsured people (12%) were noncitizens who had lived in the United States for more than 5 years.
Furthermore,aforthcomingKaiserCommissionreportthatused earlier CPS data found the number of uninsured recent immigrants actually declined by approximately 100000 from 1994 to 1998, whilethetotaluninsuredpopulationincreasedby4.2millionpeople during this period. 1 Thus, although LaPorta is correct in noting that immigrants face a greater risk of being uninsured than the US-born population, the remedies he suggests would have little impact on the number of uninsured people in the United States.
The United States is a nation of immigrants. Not only do immigrants represent 10% of the US population, but another 10% of US citizens have 1 or 2 immigrant parents, and many more citizens have 1 or more immigrant grandparents. Most immigrants arrive in the United States legally (including 85% of current immigrants 2 ) and become contributing members of society. For example, in the first of the 2 Kaiser Commission analyses described above, 68% of uninsured recent immigrants were members of households with 1 or 2 full-time workers, but many had wages too low to afford health insurance. These facts should be recognized when potential solutions to the problems of the uninsured are considered.
